Valentine Capital Asset Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Valentine Capital Asset Management’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$3.58M	Sell	50,135 -9,488	-16%	-$634K	4%	4
2015 Q3	$3.47M	Buy	59,623 +643	+1%	+$54.8K	3.07%	4
2015 Q2	$5.33M	Sell	58,980 -50,216	-46%	-$4.32M	3.59%	2
2015 Q1	$8.65M	Buy	109,196 +4,630	+4%	+$343K	2.53%	4
2014 Q4	$6.56M	Sell	104,566 -25,370	-20%	-$1.49M	1.6%	19
2014 Q3	$6.75M	Buy	129,936 +24,686	+23%	+$1.2M	2.61%	12
2014 Q2	$4.88M	Buy	105,250 +850	+0.8%	+$33.6K	0.94%	52
2014 Q1	$4.17M	Buy	104,400 +97,660	+1,449%	+$4.43M	0.87%	51
2013 Q4	$254K	Buy	+6,740	New	+$225K	0.05%	113

Other funds holding BIB

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

RIA

RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Valentine Capital Asset Management's BIB Position: Q4 2015 in Review

Valentine Capital Asset Management reduced its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 16% in Q4 2015, selling an estimated $634K and leaving 50,135 shares worth $3.58M. The position accounts for 4% of the portfolio, ranked #4.

Valentine Capital Asset Management first reported a position in BIB in Q4 2013 and has held it in 9 quarters since. The position peaked at $8.65M in Q1 2015. 27 funds tracked by Wall St. Rank hold BIB as of Q4 2015.

Valentine Capital Asset Management held 50,135 shares of ProShares Ultra NASDAQ Biotechnology worth $3.58M as of Q4 2015.
Valentine Capital Asset Management sold 9,488 ProShares Ultra NASDAQ Biotechnology shares in Q4 2015, an estimated $634K.
ProShares Ultra NASDAQ Biotechnology made up 4% of Valentine Capital Asset Management's portfolio in Q4 2015, its #4 holding.
Valentine Capital Asset Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2013 and has held it in 9 quarters since.
Valentine Capital Asset Management's ProShares Ultra NASDAQ Biotechnology position peaked at $8.65M in Q1 2015.
27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2015.

Based on Valentine Capital Asset Management's 13F filing for Q4 2015, filed 17 Feb 2016.